Coupling and uncoupling of tumor immunity and autoimmunity

Journal of Experimental Medicine

Volumn 190, Issue 11, 1999, Pages 1717-1722

  Bowne, Wilbur B ^b   Srinivasan, Roopa ^b   Wolchok, Jedd D ^b   Hawkins, William G ^b   Blachere, Nathalie E ^b   Dyall, Ruben ^b   Lewis, Jonathan J ^b   Houghton, Alan N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

Melanocyte; Melanoma; Perforin; T cell; Tyrosinase related protein

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNIZATION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

ANIMALS; ANTIBODY FORMATION; AUTOANTIBODIES; BETA 2-MICROGLOBULIN; FEMALE; HUMANS; IMMUNOTHERAPY; INTRAMOLECULAR OXIDOREDUCTASES; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; PORE FORMING CYTOTOXIC PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, ISOGENEIC; TUMOR CELLS, CULTURED;

EID: 0033432773     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.190.11.1717     Document Type: Article

References (22)

1. Houghton, A.N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1-4.
2. Houghton, A.N., M. Eisinger, A.P. Albino, J.G. Cairncross, and L.J. Old. 1982. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 156:1755-1766.
3. Vijayasaradhi, S., B. Bouchard, and A.N. Houghton. 1990. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J. Exp. Med. 171:1375-1380.
4. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. De Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178: 489-495.
5. Boyse, E.A., and L.J. Old. 1969. Some aspects of normal and abnormal cell surface genetics. Annu. Rev. Genet. 3:269-290.
6. Sakai, C., Y. Kawakami, L.W. Law, M. Furumura, and V.J. Hearing, Jr. 1997. Melanosomal proteins as melanoma-specific immune targets. Melanoma Res. 7:83-95.
7. Wang, R.-F., E. Appella, Y. Kawakami, X. Kang, and S.A. Rosenberg. 1996. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184:2207-2216.
8. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA. 91:9461-9465.
9. Bloom, M.B., D. Perry-Lalley, P.F. Robbins, Y. Li, M. el-Gamil, S.A. Rosenberg, and J.C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453-459.
10. Qin, Z., G. Richter, T. Schuler, S. Ibe, X. Cao, and T. Blankenstein. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4:627-630.
11. Parkhurst, M.R., E.B. Fitzgerald, S. Southwood, A. Sette, S.A. Rosenberg, and Y. Kawakami. 1998. Identification of a shared HLA-A(Black star)0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58:4895-4901.
12. Wang, R.F., S.L. Johnston, S. Southwood, A. Sette, and S.A. Rosenberg. 1998. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J. Immunol. 160:890-897.
13. Weber, L.W., W.B. Bowne, J.D. Wolchok, R. Srinivasan, J. Qin, Y. Moroi, R. Clynes, P. Song, J.J. Lewis, and A.N. Houghton. 1998. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest. 102:1258-1264.
14. + T lymphocytes. Proc. Natl. Acad. Sci. USA. 96:2982-2987.
15. Hara, I., Y. Takechi, and A.N. Houghton. 1995. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J. Exp. Med. 182:1609-1614.
16. Naftzger, C., K. Takechi, H. Kohda, I. Hara, S. Vijayasaradhi, and A.N. Houghton. 1996. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA. 93:14809-14814.
17. Clynes, R., Y. Takechi, Y. Moroi, A.N. Houghton, and J.V. Ravetch. 1998. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA. 95: 652-656.
18. Overwijk, W.W., A. Tsung, K.R. Irvine, M.R. Parkhurst, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenberg, and N.P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.
19. Nordlund, J.J., J.M. Kirkwood, B.M. Forget, G. Milton, D.M. Albert, and A.B. Lerner. 1983. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Dermatol. 9:689-692.
20. Bystryn, J.C., D. Rigel, R.J. Friedman, and A. Kopf. 1987. Prognostic significance of hypopigmentation in malignant melanoma. Arch. Dermatol. 123:1053-1055.
21. Rosenberg, S.A., and D.E. White. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19:81-84.
22. Richards, J.M., N. Mehta, K. Ramming, and P. Skosey. 1992. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol. 10:1338-1343.